EIN 13-1837442

Cancer Research Institute (CRI)

IRS 501(c) type
501(c)(3)
Num. employees
32
Year formed
1953
Most recent tax filings
2023-06-01
NTEE code, primary
Description
Extend the lives of cancer patients and reduce cancer-related deaths by fueling the development of a new class of smarter, more effective treatments that mobilize our body's natural immune defenses against all types of cancer.
Total revenues
$32,295,259
2023
Total expenses
$38,552,663
2023
Total assets
$138,008,864
2023
Num. employees
32
2023

Program areas at CRI

Clinical accelerator grants program - see schedule othe cri anna-maria kellen clinical accelerator : is an actively managed venture philanthropy program designed to speed the development of promising new Cancer immunotherapy combinations. This model facilitates Research collaboration across leading biopharma companies and the cri network of immuno-oncology experts. The program includes platform clinical trials that are collaborative, integrative, science/data-driven, and hypothesis-answering clinical studies. Cri plans, implements, invests in, and manages each clinical accelerator clinical trial and works closely with academic researcher and industry partners on such studies. Each clinical trial and philanthropic investment brings a potential new Cancer treatment closer to patients, empowers academic researchers to work more closely with industry, and creates a potential return on investment to be used to support furture clinical efforts.
Star program - see schedule othe lloyd j. Old star program, launched in 2019, provides grants of $1.25 million over 5 years to mid-career scientists. This longterm funding is not tied to a specific Research project, but rather aims to provide a degree of flexibility and freedom for investigators to explore outside-the-box and disruptive avenues of Research. Candidates selected for this award are expected to be future "stars" in the field of Cancer immunology: scientists taking risks.
Fellowship program - see schedule othe cri postdoctoral fellowship program includes three tracks of fellowships providing career development, training, and diversity building in immunology and immuno-infomatics. The cri irvington postdoctoral fellowship, cri irvington postdoctoral fellowship to promote racial diversity, and the cri immuno-informatics fellowship each support young immunologists and Cancer immunologists at top universities and Research centers around the world. Fellows receive up to $243,000 over three years to cover the cost of stipend, including an institutional allowance to help pay for the fellow's Research supplies, travel to scientific meetings, health insurance, and/or childcare. Of the more than 1,550 cri postdoctoral fellows funded to date, many have since become heads of major medical Research institutes, academic leaders in prestigious universities, and admired mentors to the next generation of immunologists and tumor immunologists.
Cri clinical innovator:the cri clinical innovator supports novel clinical studies that address areas of high unmet need in Cancer and seek mechanistic insights into clinical response with a goal of predictive biomarker discovery. To maximize the impact of each clinical trial, cri will advise on selected studies in a coordinated effort to optimize clinical trial design and translational studies. Funding of up to $1m per trial is awarded.clinic and laboraty integration program (clip):the cri clinic and laboratory integration program (clip) supports pre-clinical and translational Research that can be directly applied to optimizing Cancer immunotherapy in the clinic. Clip grants are awarded to qualified scientists exploring clinically relevant questions aimed at improving the effectiveness of Cancer immunotherapies. Clip grants provide up to $300,000 over two years. Technology impact award:the cri technology impact award provides seed funding of up to $200,000 to be used over 24 months to address the gap between technology development and clinical application of Cancer immunotherapies.cri impact grants:cri impact grants support Research projects and public education and awareness initiatives within or applicable to the fields of immunology and tumor immunology for which funds have been specifically raised.

Grants made by CRI

GranteeGrant descriptionAmount
Johns Hopkins University (JHU)Research$9,002,197
Dana-Farber Cancer InstituteResearch$1,535,000
Icahn School of Medicine at Mount SinaiResearch$1,464,497
...and 28 more grants made totalling $22,249,339

Who funds Cancer Research Institute (CRI)

Grants from foundations and other nonprofits
GrantmakerDescriptionAmount
Robertson FoundationLloyd J. Old Star Program$2,625,000
Anna Maria and Stephen Kellen FoundationGeneral Tax Exempt Purposes$1,050,000
Alliance for Cancer Gene TherapyCancer Research$750,000
...and 202 more grants received totalling $12,206,352

Personnel at CRI

NameTitleCompensation
Jill O'Donnell-TormeyChief Executive Officer and Director of Scientific Affairs$531,286
Alfred MassidasChief Financial Officer and Director of Human Resources$342,586
Sharon SladeChief Marketing Officer$259,188
Rupinder KaurChief Information Officer$224,014
Brian R LeidyChief Development Officer$199,545
...and 19 more key personnel

Financials for CRI

RevenuesFYE 06/2023
Total grants, contributions, etc.$31,020,217
Program services$0
Investment income and dividends$644,951
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$29,319
Net gain from sale of non-inventory assets$546,052
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$54,720
Total revenues$32,295,259

Form 990s for CRI

Fiscal year endingDate received by IRSFormPDF link
2023-062024-03-18990View PDF
2022-062023-02-07990View PDF
2021-062022-02-07990View PDF
2020-062021-04-06990View PDF
2019-062020-08-27990View PDF
...and 10 more Form 990s
Data update history
August 25, 2024
Received grants
Identified 68 new grant, including a grant for $1,050,000 from Anna Maria and Stephen Kellen Foundation
May 19, 2024
Posted financials
Added Form 990 for fiscal year 2023
May 19, 2024
Used new vendors
Identified 1 new vendor, including
May 17, 2024
Received grants
Identified 5 new grant, including a grant for $250,000 from Frank V Sica and Colleen Mcmahon Foundation
January 24, 2024
Updated personnel
Identified 9 new personnel
Nonprofit Types
Grantmaking organizationsDisease research fundraisersMedical research organizationsCharities
Issues
HealthDiseases and disordersCancer
Characteristics
Provides grantsConducts researchFundraising eventsOperates internationallyNational levelEndowed supportCommunity engagement / volunteeringTax deductible donationsAccepts online donations
General information
Address
29 Broadway 4th Floor
New York, NY 10006
Metro area
New York-Newark-Jersey City, NY-NJ-PA
County
New York County, NY
Website URL
cancerresearch.org/ 
Phone
(212) 688-7515
Facebook page
CancerResearchInstituteInc 
Twitter profile
@cancerresearch 
IRS details
EIN
13-1837442
Fiscal year end
June
Taxreturn type
Form 990
Year formed
1953
Eligible to receive tax-deductible contributions (Pub 78)
Yes
Categorization
NTEE code, primary
H30: Cancer Research
NAICS code, primary
813212: Health and Disease Research Fundraising Organizations
Parent/child status
Independent
California AB-488 details
AB 488 status
May Operate or Solicit for Charitable Purposes
Charity Registration status
Current
FTB status revoked
Not revoked
AG Registration Number
019617
FTB Entity ID
0811158
AB 488 data last updated ("as-of") date
2024-10-16
Free account sign-up

Want updates when CRI has new information, or want to find more organizations like Cancer Research Institute (CRI)?

Create free Cause IQ account